Updated: May 2017
Overview
Patient Experience
Initiative
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 2
Our Innovative Leaders
TransCelerate BioPharma is proud
to have leadership from major
biopharmaceutical companies –
who have dedicated their careers
to medicine, science and ensuring
access to life-saving medicines
through efficient and safe research
and development.
We are fortunate to have the
greatest minds in pharmaceutical
R&D dedicated towards this
common goal of identifying
common issues and model solutions
that will drive efficiencies into the
R&D process.
About TransCelerate
TransCelerate BioPharma Inc.
was launched in 2012 as a
non-profit organization with a
mission to collaborate across
the biopharmaceutical
research and development
community to identify, design
and facilitate the
implementation of solutions to
drive efficient, effective and
high-quality delivery of new
medicines, improving the
health of people around the
world.
Our Mission Statement
TransCelerate BioPharma’s mission is
to collaborate across the global
biopharmaceutical research and
development community to identify,
prioritize, design and facilitate
implementation of solutions designed
to drive the efficient, effective and
high quality delivery of new
medicines.
Our Members
TransCelerate BioPharma is
comprised of the world’s leading
biopharmaceutical companies, with
the vision of accelerating and
enhancing the research and
development of innovative new
therapies. The spirit of innovation and
collaboration occurs across
TransCelerate Member
Companies on Initiative goals.
Welcome to
TransCelerate BioPharma Inc.
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 3
TABLE OF CONTENTS
Workstream Overview
Value Proposition
Stakeholder Benefit / Impact
Deliverable Overview / Illustrative Example
Upcoming Milestones
Team Composition
Additional Resources
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 4
Enable greater patient engagement and partnership with sponsors to design and execute
clinical protocols that create better patient experiences in clinical trials.
Study
Design
Scientific
Objectives
Procedures
& Assessments
Schedule
of Activities
Diverse Patient Populations Sponsors, Sites, Investigators
Develop shared understanding of how…
Translates into…
Reduced Patient
Burden
Perception
of Value
Patient
Empowerment
Willingness to
Participate
Patient Experience Workstream Vision
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 5
Patient Experience Value Proposition
Workstream Deliverables Value Propositions
• There is no widely
accepted framework to
understand and
measure the patient
experience in trials
• Tools for clinical teams
to engage patients in
the study design and
execution stages of
clinical trials
• Frameworks to increase
the patient centricity of
study programs with a
measureable
methodology
• Better understanding
and measurement of
patient experiences in
clinical trials to increase
their willingness to
participate in clinical
trials• Without this framework it
is difficult for sponsors to
translate patient
engagement into
actionable insights that
measure improvements
in study design and
execution for patients
(i.e. ROE)
• Improved patient
experiences throughout
their clinical trial
experience
Unmet Needs
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 6
Stakeholder Benefits and Impacts
•Potential improvement in patient
recruitment, retention, & adherence
within clinical trials
•Potential reduction in long term costs
through more effective patient
engagement
•Enhanced patient feedback process
that improves outcomes across the
industry
•Increased trust and engagement
through better communication, and
participation in feedback processes
•Increased understanding of the value
in participating in clinical trials
•Potential decrease in the burden of
participating in clinical trials
•Potential increase in the sense of
altruism due to the confidence of
knowing that their participation in trials
may improve future study volunteers’
experiences
PatientsSponsors, Sites, and Investigators
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 7
PE Deliverables
Patient Centric Protocol Discussion Guide Toolkit (DGT):
• User Guide – A document with instructions that explain the most efficient and effective
ways to implement and utilize the DGT
• Discussion Guide – A discussion guide that leverages a scientifically robust framework for
engaging and eliciting feedback with patient advisors during the protocol design phase
• Patient Insights Report Template – A reporting template that includes considerations and
options on how to address patients’ concerns with protocol design choices
Patient Experience Questionnaire Toolkit (PEQT):
• User Guide – A document with instructions that explain the most efficient and effective
ways to implement and utilize the PEQT
• Patient Experience Questionnaire – A qualitative / quantitative questionnaire with a
“question bank” format used with live patients in the study conduct phase
• Summary of PEQ Results Template – A reporting template that includes lessons learned to
inform the design of the next study
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 8
STUDY PROTOCOL DESIGN PHASE
STUDY
CONDUCT
STUDY
CLOSE-OUT
ClinicalProgramTeams
Develop
(Draft)
protocol
Populate
Discussion
Guide
Engage
Patients
Protocol
Concept
Example clinical trial process with the
Discussion Guide Toolkit (DGT) and Patient
Experience Questionnaire Toolkit (PEQT)
Conduct
Internal
Assessment
of Patient
insights
Report format includes
considerations and
options on how to
address patients’
concerns with the
burdensome elements
of the protocol
As Needed
Revise/
Finalize
Protocol
Discussion
Guide
Outline
(Populated)
Discussion
Guide
Ongoing
Study
Assessments
Patient Experience Questionnaire
Conduct Exit
Survey
Summarize
Key Findings
Key findings
for next
protocol to
consider
(Populated) PEQ
Summary Findings
Report Template
Next
Protocol
Report format
includes lessons
learned and can
include optional
reconciliation with
design phase
“Patient insights
report” to inform
next study
(Populated)
Patient Insights
Report Template
Patient Experience Questionnaire (PEQ)
will be in a “question bank” format with
different potential use-cases:
• In trial patient questionnaire
• In trial site staff observer questionnaire
• Exit interview patient questionnaire
Key
Process
Initiation
Process
Completion
Phase 1
Process Step
DGT
Deliverables
PEQT
Deliverables
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 9
Upcoming Milestones
2017 Major Milestones
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
March.
Workstream plan
and delivery
timelines
established
June. .
Complete first round
of primary research
with patients, sites,
sponsors for concept
elicitation
December.
Finalize
deliverables
for 2018 pilots
October.
Complete second
round of primary
research with
stakeholders for
cognitive debriefs
July.
Complete
1st drafts of
deliverables
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 10
Who’s Involved with PE
Workstream Leads
Core Team
Fabian Somers (Allergan) & Stephen Yates (UCB)
* NOTE: Participating on the Working Groups does not require implementation of the workstream’s solutions
THANK YOU

TransCelerate Overview - Patient Experience Initiative

  • 1.
  • 2.
    Copyright ©2015 TransCelerateBioPharma Inc., All rights reserved. 2 Our Innovative Leaders TransCelerate BioPharma is proud to have leadership from major biopharmaceutical companies – who have dedicated their careers to medicine, science and ensuring access to life-saving medicines through efficient and safe research and development. We are fortunate to have the greatest minds in pharmaceutical R&D dedicated towards this common goal of identifying common issues and model solutions that will drive efficiencies into the R&D process. About TransCelerate TransCelerate BioPharma Inc. was launched in 2012 as a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, design and facilitate the implementation of solutions to drive efficient, effective and high-quality delivery of new medicines, improving the health of people around the world. Our Mission Statement TransCelerate BioPharma’s mission is to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. Our Members TransCelerate BioPharma is comprised of the world’s leading biopharmaceutical companies, with the vision of accelerating and enhancing the research and development of innovative new therapies. The spirit of innovation and collaboration occurs across TransCelerate Member Companies on Initiative goals. Welcome to TransCelerate BioPharma Inc.
  • 3.
    Copyright ©2015 TransCelerateBioPharma Inc., All rights reserved. 3 TABLE OF CONTENTS Workstream Overview Value Proposition Stakeholder Benefit / Impact Deliverable Overview / Illustrative Example Upcoming Milestones Team Composition Additional Resources
  • 4.
    Copyright ©2015 TransCelerateBioPharma Inc., All rights reserved. 4 Enable greater patient engagement and partnership with sponsors to design and execute clinical protocols that create better patient experiences in clinical trials. Study Design Scientific Objectives Procedures & Assessments Schedule of Activities Diverse Patient Populations Sponsors, Sites, Investigators Develop shared understanding of how… Translates into… Reduced Patient Burden Perception of Value Patient Empowerment Willingness to Participate Patient Experience Workstream Vision
  • 5.
    Copyright ©2015 TransCelerateBioPharma Inc., All rights reserved. 5 Patient Experience Value Proposition Workstream Deliverables Value Propositions • There is no widely accepted framework to understand and measure the patient experience in trials • Tools for clinical teams to engage patients in the study design and execution stages of clinical trials • Frameworks to increase the patient centricity of study programs with a measureable methodology • Better understanding and measurement of patient experiences in clinical trials to increase their willingness to participate in clinical trials• Without this framework it is difficult for sponsors to translate patient engagement into actionable insights that measure improvements in study design and execution for patients (i.e. ROE) • Improved patient experiences throughout their clinical trial experience Unmet Needs
  • 6.
    Copyright ©2015 TransCelerateBioPharma Inc., All rights reserved. 6 Stakeholder Benefits and Impacts •Potential improvement in patient recruitment, retention, & adherence within clinical trials •Potential reduction in long term costs through more effective patient engagement •Enhanced patient feedback process that improves outcomes across the industry •Increased trust and engagement through better communication, and participation in feedback processes •Increased understanding of the value in participating in clinical trials •Potential decrease in the burden of participating in clinical trials •Potential increase in the sense of altruism due to the confidence of knowing that their participation in trials may improve future study volunteers’ experiences PatientsSponsors, Sites, and Investigators
  • 7.
    Copyright ©2015 TransCelerateBioPharma Inc., All rights reserved. 7 PE Deliverables Patient Centric Protocol Discussion Guide Toolkit (DGT): • User Guide – A document with instructions that explain the most efficient and effective ways to implement and utilize the DGT • Discussion Guide – A discussion guide that leverages a scientifically robust framework for engaging and eliciting feedback with patient advisors during the protocol design phase • Patient Insights Report Template – A reporting template that includes considerations and options on how to address patients’ concerns with protocol design choices Patient Experience Questionnaire Toolkit (PEQT): • User Guide – A document with instructions that explain the most efficient and effective ways to implement and utilize the PEQT • Patient Experience Questionnaire – A qualitative / quantitative questionnaire with a “question bank” format used with live patients in the study conduct phase • Summary of PEQ Results Template – A reporting template that includes lessons learned to inform the design of the next study
  • 8.
    Copyright ©2015 TransCelerateBioPharma Inc., All rights reserved. 8 STUDY PROTOCOL DESIGN PHASE STUDY CONDUCT STUDY CLOSE-OUT ClinicalProgramTeams Develop (Draft) protocol Populate Discussion Guide Engage Patients Protocol Concept Example clinical trial process with the Discussion Guide Toolkit (DGT) and Patient Experience Questionnaire Toolkit (PEQT) Conduct Internal Assessment of Patient insights Report format includes considerations and options on how to address patients’ concerns with the burdensome elements of the protocol As Needed Revise/ Finalize Protocol Discussion Guide Outline (Populated) Discussion Guide Ongoing Study Assessments Patient Experience Questionnaire Conduct Exit Survey Summarize Key Findings Key findings for next protocol to consider (Populated) PEQ Summary Findings Report Template Next Protocol Report format includes lessons learned and can include optional reconciliation with design phase “Patient insights report” to inform next study (Populated) Patient Insights Report Template Patient Experience Questionnaire (PEQ) will be in a “question bank” format with different potential use-cases: • In trial patient questionnaire • In trial site staff observer questionnaire • Exit interview patient questionnaire Key Process Initiation Process Completion Phase 1 Process Step DGT Deliverables PEQT Deliverables
  • 9.
    Copyright ©2015 TransCelerateBioPharma Inc., All rights reserved. 9 Upcoming Milestones 2017 Major Milestones Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec March. Workstream plan and delivery timelines established June. . Complete first round of primary research with patients, sites, sponsors for concept elicitation December. Finalize deliverables for 2018 pilots October. Complete second round of primary research with stakeholders for cognitive debriefs July. Complete 1st drafts of deliverables
  • 10.
    Copyright ©2015 TransCelerateBioPharma Inc., All rights reserved. 10 Who’s Involved with PE Workstream Leads Core Team Fabian Somers (Allergan) & Stephen Yates (UCB) * NOTE: Participating on the Working Groups does not require implementation of the workstream’s solutions
  • 11.